Today on Drug Discovery & Development
With Deep Research, the CEO of OMNY Health says we’re still ‘in the first inning’ of AI-assisted research
It may not be perfect, but OpenAI’s Deep Research tool can significantly accelerate mundane internet-based research tasks. You give it an assignment, it asks a few follow-up questions, which you reply and there it goes, thinking and researching your query for about five minutes — or as long as half an hour. Built on OpenAI’s…
Flatiron Health sees shift from “what if” to “what is” in real-world evidence in oncology
“The era of ‘what if’ for AI in healthcare is over. Now, it’s all about ‘what is.’ ” So says Blythe Adamson, head of outcomes research and evidence generation at the real-world evidence platform Flatiron Health, a company reimagining cancer care infrastructure. “Post-ChatGPT,” she states, “the skepticism has vanished.” The proof? Flatiron is seeing data…
Drug Discovery and Development See More >
How a ‘rising tide’ of inclusivity is transforming clinical trials
Let’s say there’s a Black female patient with an aggressive form of breast cancer. She meets with her oncologist to discuss a promising targeted therapy that recently won FDA approval. The drug showed strong efficacy in clinical trials, with a 65% response rate. Yet when she asks about efficacy data specific to Black women, she…
Mary Marcus appointed CEO of NewAge Industries
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
External comparator studies: What researchers need to know to minimize bias
Tiny breaths, big impacts: Bridging the gap between laboratory discoveries and clinical applications in breath research with mouse models
Sponsored Content See More >
Complexity’s counterpoint: Understanding protocol optimization In recent years, the clinical research landscape has been marked by a steady rise in protocol complexity with more endpoints…
Optimizing Data Pipelines in Life Sciences with AI-Driven Integration and FHIRSponsored by Infor. Data management in life sciences is inherently complex. Data is fragmented across multiple systems — such…
Accelerating life sciences with AI This case study is sponsored by Infor. Artificial intelligence can revolutionize clinical interoperability by building bridges across data silos. Machine…
Advancing Clinical Trials and ResearchThis case study is sponsored by Infor. In the complex landscape of clinical trials and medical research, data fragmentation remains…
Multidisciplinary approaches optimize contract drug discovery
5 Key Questions in Conducting Global Usability StudiesBy Dr Bryce G Rutter, Head Noble Consulting Services Evaluating device usability throughout the product development process is crucial. A…
Leveraging HF/UX/ID Services to Optimize the Design of Combination Devices for Arthritic HandsBy Dr. Bryce G Rutter, Head of Consulting Services Arthritis changes how people grasp and manipulate an object, reducing the…
Ask the Expert: Navigating the New FDA Rules on Laboratory Developed Tests (LDTs)The U.S. FDA released a final rule to regulate laboratory developed tests (LDTs) on May 6, 2024, making it clear…
How tailored qPCR assays can unlock microbiome and precision medicine potential Sponsored by Diversigen, Inc. Quantitative Polymerase Chain Reaction (qPCR) — also known as real-time PCR — is a molecular…
Innovations in Baculovirus–Insect Cell Expression SystemsThe baculovirus–insect cell expression system—insect cells used in conjunction with the baculovirus expression vector system (BEVS)—remains a crucial technology for…
Patient Training is Broken – And Everyone is Paying For ItNoble International is working with Pharma and Specialty Pharmacy to fix the problem. The report, “The Current Paradigm for Biologic…
Noble Leads with its User-Centered Design StrategyBy Tim McLeroy, Executive Director of Marketing and Patient Services, Noble International At Noble, the patient journey drives everything we…
Genomics/Proteomics See More >
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
In 2025, genetic validation is poised to emerge as a high-stakes litmus test in cardiovascular R&D, investors will continue to get better at funneling cash into proven science, and patients will continue their evolution to become more-active partners shaping their healthcare. To hear more about each of these trends, we considered feedback from three industry…
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
St. Jude pioneers gene editing and structural biology to advance pediatric research
![A display of DNA sequencing output from an automated ABI 373 sequencer. [National Human Genome Research Institute (NHGRI)]](https://www.drugdiscoverytrends.com/wp-content/uploads/2024/06/51187236177_b7b566a401_k-268x170.jpg)
Helix and Recursion join forces in quest to crack the AI-driven drug discovery code
Athos Therapeutics chooses Vultr’s private cloud to power AI drug discovery engine
Infectious Disease See More >
Advances in next generation vaccine development for SARS-CoV-2
Typical COVID-19 vaccines present fragments of the SARS-CoV-2 spike protein to the body, enabling the immune system to recognize and develop a defense against the virus. However, emerging variants are increasingly evading this immune response due to mutations in their receptor-binding domain (RBD), threatening the effectiveness of existing vaccines. This challenge has prompted research into…
World AIDS Day Summit & Celebration slated for early December
Moderna and Pfizer win approval for KP.2 vaccine as KP.3 variants account for about half of current cases
Moderna’s single-dose mRNA RSV vaccine, mRESVIA, gains FDA approval for adults 60+
Best-selling pharmaceuticals of 2023 reveal a shift in pharma landscape
Oncology See More >
Flatiron Health sees shift from “what if” to “what is” in real-world evidence in oncology
“The era of ‘what if’ for AI in healthcare is over. Now, it’s all about ‘what is.’ ” So says Blythe Adamson, head of outcomes research and evidence generation at the real-world evidence platform Flatiron Health, a company reimagining cancer care infrastructure. “Post-ChatGPT,” she states, “the skepticism has vanished.” The proof? Flatiron is seeing data…
